Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
Programs to incentivise antibiotic R&D are underway in the UK and under consideration in the US, EU, Canada, and Japan. We have assessed the benefits and costs to the members of the G7/EU and project that all G7/EU members would see big payoffs ranging from 11:1 in the UK to 28:1 for the US and Japan. Global returns from reducing the 1.27m people dying each year from AMR are even higher.
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
Since the Office of Health Economics (OHE) published a critique of CBO’s new simulation model of new drug development late last year, the U.S. public sector think tank has made three improvements to its methodology. We review these updates, assess their impact, and highlight the key remaining limitations of the modelling approach, concluding that policymakers should still exercise considerable caution in relying on its predictions.
Invest to End TB. Save Lives. World TB Day 2022. Reflections on 60 years of OHE publications on TB
24 March 2022
Global TB deaths are increasing. CGD and OHE set out a “Market-Driven, Value-Based, Advance Commitment (MVAC)” that would create and guarantee a market for a breakthrough…
How Does Pharmaceutical Spending Drive Innovation in Europe?
7 February 2022
A new publication by Kourouklis and Gandjour (2022) investigates the impact of pharmaceutical spending on domestic early-stage pharmaceutical innovation in Europe. They find that European spending…
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
1 June 2022
In recent years, U.S. policymakers have been considering reforms to tackle high and rising prescription drug spending, including unprecedented direct limits on prices and price growth…
Virtual OHE Annual Lecture 2021: Do Patents Work? Evidence from Pharmaceutical Innovation
28 September 2021
The exceptional circumstances of COVID-19 revived the controversy around patents of pharmaceutical products. A group of specialists suggested that the Trade-Related Aspects of Intellectual Property Rights…
How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? Where are we 6 Months on?
1 July 2021
The Value in Health May issue includes the paper “How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?”. Finalised in December 2020, it includes:…
Towards a New Understanding of Unmet Medical Need
22 June 2021
In a commentary piece recently published in Applied Health Economics and Health Policy, OHE authors discuss how the misalignment in interpretations of the term ‘unmet medical…
Would Waiving COVID-19 Vaccines Patents Save Lives?
18 May 2021
This blog discusses the rationale behind a COVID-19 patent waiver decision and contributes to the current debate by producing a balanced view on the benefits and…